Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Current Deferred Revenue (2024 - 2025)

Fennec Pharmaceuticals' Current Deferred Revenue history spans 2 years, with the latest figure at $248000.0 for Q4 2025.

  • For the quarter ending Q4 2025, Current Deferred Revenue changed 0.0% year-over-year to $248000.0, compared with a TTM value of $248000.0 through Dec 2025, changed 0.0%, and an annual FY2025 reading of $248000.0, changed 0.0% over the prior year.
  • Current Deferred Revenue for Q4 2025 was $248000.0 at Fennec Pharmaceuticals, roughly flat from $248000.0 in the prior quarter.
  • The five-year high for Current Deferred Revenue was $252000.0 in Q1 2024, with the low at $248000.0 in Q3 2024.